查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1726238

Aminoglycosides市場規模、佔有率、趨勢分析報告：按產品、給藥途徑、應用、地區、細分市場預測，2025-2030 年

Aminoglycosides Market Size, Share & Trends Analysis Report By Product, By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 105 Pages | 商品交期: 2-10個工作天內

價格

Aminoglycosides市場的成長與趨勢

根據 Grand View Research, Inc. 的新報告，預計到 2030 年全球Aminoglycosides市場規模將達到 24.5 億美元。

預計 2025 年至 2030 年間，市場複合年成長率將達到 4.34%。隨著動物疾病發病率的增加，導致抗生素的廣泛使用，預計需求將增加。

然而，由於嚴重的耳毒性、腎毒性和神經肌肉阻斷等副作用，Aminoglycosides抗生素的普及率預計會下降，對市場成長產生不利影響。此外，監管機構不贊成使用某些Aminoglycosides抗生素也預計會減緩該行業的成長。

Aminoglycosides市場報告重點

  • 預計預測期內妥布黴素市場將顯著成長。妥布黴素是一種強效Aminoglycosides抗生素，由於其對革蘭氏陰性細菌，尤其是銅綠假單胞菌具有頻譜功效，在全球Aminoglycosides抗生素行業中佔有重要地位。
  • 根據給藥途徑，市場細分為注射劑、飼料、乳房內、局部、口服和注射劑，其中注射劑在 2024 年的市場佔有率為 26.73%。
  • 預計在預測期內，皮膚感染疾病將以最快的複合年成長率成長。皮膚感染疾病是市場的主要驅動力，因為其盛行率高，而且Aminoglycosides在治療革蘭氏陰性病菌感染有效。
  • 2024 年，北美Aminoglycosides製藥業將佔全球銷售額的 37.60%。這一巨大佔有率是由於北美普遍存在的細菌感染以及影響數百萬人的成熟醫療保健基礎設施。

目錄

第1章調查方法與範圍

第2章執行摘要

第3章Aminoglycosides市場變數、趨勢與範圍

  • 市場體系展望
    • 母市場展望
    • 相關/附隨市場展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • Aminoglycosides市場分析工具
    • 產業分析—波特五力分析
    • PESTEL分析
    • 定價分析
    • 管道分析

第4章Aminoglycosides市場：產品、估計與趨勢分析

  • 全球Aminoglycosides市場：產品儀表板
  • 全球Aminoglycosides藥物市場：產品差異分析
  • 全球Aminoglycosides市場（按產品和收益）
  • 新黴素
  • 妥布黴素
  • 慶大霉素
  • Amikacin
  • Paromomycin
  • 鏈黴素
  • 卡那黴素
  • 其他

第5章Aminoglycosides市場：依給藥途徑、估計及趨勢分析

  • 全球Aminoglycosides市場：給藥途徑儀表板
  • 全球Aminoglycosides市場：給藥途徑變異分析
  • 全球Aminoglycosides市場（依給藥途徑及收益）
  • 注射
  • 餵食
  • 在乳房中
  • 局部的
  • 口服

第6章Aminoglycosides市場：應用、預測與趨勢分析

  • 全球Aminoglycosides市場：應用儀表板
  • 全球Aminoglycosides市場：應用趨勢分析
  • 全球Aminoglycosides市場（按應用和收益）
  • 皮膚感染疾病
  • 尿道感染及骨盆腔疾病
  • 獸醫
  • 呼吸系統疾病
  • 其他

第7章Aminoglycosides市場：按治療、治療層級和地區分類的估計和趨勢分析

  • 區域儀表板
  • 2018-2030年市場規模、預測趨勢分析
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 挪威
    • 瑞典
    • 丹麥
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭態勢

  • 主要市場參與企業的近期趨勢和影響分析
  • 公司/競爭對手分類
  • 供應商格局
    • 主要經銷商和通路合作夥伴名單
    • 2024年主要企業市場佔有率分析
    • Pfizer Inc.
    • Merck & Co. Inc.
    • AbbVie Inc.
    • Teva Pharmaceutical Industries Ltd
    • Cipla
    • Sun Pharmaceutical Industries Ltd.
    • Lupin
    • Aurobindo Pharma Limited
    • Fresenius Kabi
    • Viatris Inc.
Product Code: 978-1-68038-630-1

Aminoglycoside Market Growth & Trends:

The global aminoglycosides market size is anticipated to reach USD 2.45 billion by 2030, according to a new report by Grand View Research, Inc. The market is projected to grow at a CAGR of 4.34% from 2025 to 2030. This expected growth in demand can be ascribed to the increasing incidences of animal disease outbreaks leading to high utilization of antibiotics.

However, reduction in prescription rate of aminoglycoside antibiotics due to side effects associated with usage of these drugs that include severe ototoxicity, nephrotoxicity, and neuromuscular blockade are expected to affect the market growth negatively. Furthermore, regulatory disapproval for the usage of certain aminoglycoside in regions is also anticipated to attribute for subordinate growth in this industry.

Aminoglycoside Market Report Highlights:

  • Tobramycin is expected to exhibit significant growth in the market over the forecast period. It is a potent aminoglycoside antibiotic that plays a critical role in the global aminoglycosides industry due to its broad-spectrum efficacy against Gram-negative bacteria, particularly Pseudomonas aeruginosa.
  • Based on route of administration, the market is categorized into injectable, feed, intra-mammary, topical, oral, and injectable, led the market with a market share of 26.73% in 2024.
  • Skin infections are anticipated to grow at the fastest CAGR over the forecast period. Skin infections represent a significant driver for the market, owing to their high prevalence and the effectiveness of aminoglycosides in treating gram-negative bacterial infections.
  • The North America aminoglycosides industry held 37.60% of the global revenue share in 2024. This large share is attributed to bacterial infections, which are dominant in North America, and a well-established healthcare infrastructure affecting millions of people.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Product
    • 1.2.2. Route of Administration
    • 1.2.3. Application
    • 1.2.4. Regional scope
    • 1.2.5. Estimates and forecasts timeline
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased database
    • 1.4.2. GVR's internal database
    • 1.4.3. Secondary sources
    • 1.4.4. Primary research
    • 1.4.5. Details of primary research
      • 1.4.5.1. Data for primary interviews in North America
      • 1.4.5.2. Data for primary interviews in Europe
      • 1.4.5.3. Data for primary interviews in Asia Pacific
      • 1.4.5.4. Data for primary interviews in Latin America
      • 1.4.5.5. Data for Primary interviews in MEA
  • 1.5. Information or Data Analysis
    • 1.5.1. Data analysis models
  • 1.6. Market Formulation & Validation
  • 1.7. Model Details
    • 1.7.1. Commodity flow analysis (Model 1)
    • 1.7.2. Approach 1: Commodity flow approach
    • 1.7.3. Volume price analysis (Model 2)
    • 1.7.4. Approach 2: Volume price analysis
  • 1.8. List of Secondary Sources
  • 1.9. List of Primary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
    • 2.2.1. Product and route of administration outlook
    • 2.2.2. Application outlook
    • 2.2.3. Regional outlook
  • 2.3. Competitive Insights

Chapter 3. Aminoglycosides Market Variables, Trends & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent market outlook
    • 3.1.2. Related/ancillary market outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market driver analysis
      • 3.2.1.1. Increasing prevalence of bacterial infections
      • 3.2.1.2. Advancements in drug development
      • 3.2.1.3. Growing awareness and diagnosis
    • 3.2.2. Market restraint analysis
      • 3.2.2.1. High cost of development
      • 3.2.2.2. Regulatory challenges for new drug approvals
  • 3.3. Aminoglycosides Market Analysis Tools
    • 3.3.1. Industry Analysis - Porter's
      • 3.3.1.1. Supplier power
      • 3.3.1.2. Buyer power
      • 3.3.1.3. Substitution threat
      • 3.3.1.4. Threat of new entrant
      • 3.3.1.5. Competitive rivalry
    • 3.3.2. PESTEL Analysis
      • 3.3.2.1. Political landscape
      • 3.3.2.2. Technological landscape
      • 3.3.2.3. Economic landscape
    • 3.3.3. Pricing Analysis
    • 3.3.4. Pipeline Analysis
      • 3.3.4.1. Phase 1
      • 3.3.4.2. Phase 2
      • 3.3.4.3. Phase 2

Chapter 4. Aminoglycosides Market: Treatment Estimates & Trend Analysis

  • 4.1. Global Aminoglycosides Market: Product Dashboard
  • 4.2. Global Aminoglycosides Market: Product Movement Analysis
  • 4.3. Global Aminoglycosides Market by Product, Revenue
  • 4.4. Neomycin
    • 4.4.1. Neomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.5. Tobramycin
    • 4.5.1. Tobramycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.6. Gentamicin
    • 4.6.1. Gentamicin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.7. Amikacin
    • 4.7.1. Amikacin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.8. Paromomycin
    • 4.8.1. Paromomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.9. Streptomycin
    • 4.9.1. Streptomycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.10. Kanamycin
    • 4.10.1. Kanamycin market estimates and forecasts 2018 to 2030 (USD Million)
  • 4.11. Others
    • 4.11.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 5. Aminoglycosides Market: Route of Administration Estimates & Trend Analysis

  • 5.1. Global Aminoglycosides Market: Route of Administration Dashboard
  • 5.2. Global Aminoglycosides Market: Route of Administration Movement Analysis
  • 5.3. Global Aminoglycosides Market by Route of Administration, Revenue
  • 5.4. Injectable
    • 5.4.1. Injectable monoclonal antibodies market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.5. Feed
    • 5.5.1. Feed market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.6. Intra-mammary
    • 5.6.1. Intra-mammary market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.7. Topical
    • 5.7.1. Topical market estimates and forecasts 2018 to 2030 (USD Million)
  • 5.8. Oral
    • 5.8.1. Oral market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 6. Aminoglycosides Market: Application Estimates & Trend Analysis

  • 6.1. Global Aminoglycosides Market: Application Dashboard
  • 6.2. Global Aminoglycosides Market: Application Movement Analysis
  • 6.3. Global Aminoglycosides Market by Application, Revenue
  • 6.4. Skin Infection
    • 6.4.1. Skin infection market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.5. UTI & Pelvic Diseases
    • 6.5.1. UTI & pelvic diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.6. Veterinary
    • 6.6.1. Veterinary market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.7. Respiratory diseases
    • 6.7.1. Respiratory diseases market estimates and forecasts 2018 to 2030 (USD Million)
  • 6.8. Others
    • 6.8.1. Others market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 7. Aminoglycosides Market: Regional Estimates & Trend Analysis by Treatment, Therapeutic Class, and Route of Administration

  • 7.1. Regional Dashboard
  • 7.2. Market Size, & Forecasts Trend Analysis, 2018 to 2030:
  • 7.3. North America
    • 7.3.1. U.S.
      • 7.3.1.1. Key country dynamics
      • 7.3.1.2. Regulatory framework/ reimbursement structure
      • 7.3.1.3. Competitive scenario
      • 7.3.1.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.2. Canada
      • 7.3.2.1. Key country dynamics
      • 7.3.2.2. Regulatory framework/ reimbursement structure
      • 7.3.2.3. Competitive scenario
      • 7.3.2.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.3.3. Mexico
      • 7.3.3.1. Key country dynamics
      • 7.3.3.2. Regulatory framework/ reimbursement structure
      • 7.3.3.3. Competitive scenario
      • 7.3.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.4. Europe
    • 7.4.1. UK
      • 7.4.1.1. Key country dynamics
      • 7.4.1.2. Regulatory framework/ reimbursement structure
      • 7.4.1.3. Competitive scenario
      • 7.4.1.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.2. Germany
      • 7.4.2.1. Key country dynamics
      • 7.4.2.2. Regulatory framework/ reimbursement structure
      • 7.4.2.3. Competitive scenario
      • 7.4.2.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.3. France
      • 7.4.3.1. Key country dynamics
      • 7.4.3.2. Regulatory framework/ reimbursement structure
      • 7.4.3.3. Competitive scenario
      • 7.4.3.4. France market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.4. Italy
      • 7.4.4.1. Key country dynamics
      • 7.4.4.2. Regulatory framework/ reimbursement structure
      • 7.4.4.3. Competitive scenario
      • 7.4.4.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.5. Spain
      • 7.4.5.1. Key country dynamics
      • 7.4.5.2. Regulatory framework/ reimbursement structure
      • 7.4.5.3. Competitive scenario
      • 7.4.5.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.6. Norway
      • 7.4.6.1. Key country dynamics
      • 7.4.6.2. Regulatory framework/ reimbursement structure
      • 7.4.6.3. Competitive scenario
      • 7.4.6.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.7. Sweden
      • 7.4.7.1. Key country dynamics
      • 7.4.7.2. Regulatory framework/ reimbursement structure
      • 7.4.7.3. Competitive scenario
      • 7.4.7.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.4.8. Denmark
      • 7.4.8.1. Key country dynamics
      • 7.4.8.2. Regulatory framework/ reimbursement structure
      • 7.4.8.3. Competitive scenario
      • 7.4.8.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.5. Asia Pacific
    • 7.5.1. Japan
      • 7.5.1.1. Key country dynamics
      • 7.5.1.2. Regulatory framework/ reimbursement structure
      • 7.5.1.3. Competitive scenario
      • 7.5.1.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. China
      • 7.5.2.1. Key country dynamics
      • 7.5.2.2. Regulatory framework/ reimbursement structure
      • 7.5.2.3. Competitive scenario
      • 7.5.2.4. China market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. India
      • 7.5.3.1. Key country dynamics
      • 7.5.3.2. Regulatory framework/ reimbursement structure
      • 7.5.3.3. Competitive scenario
      • 7.5.3.4. India market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Australia
      • 7.5.4.1. Key country dynamics
      • 7.5.4.2. Regulatory framework/ reimbursement structure
      • 7.5.4.3. Competitive scenario
      • 7.5.4.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. South Korea
      • 7.5.5.1. Key country dynamics
      • 7.5.5.2. Regulatory framework/ reimbursement structure
      • 7.5.5.3. Competitive scenario
      • 7.5.5.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Thailand
      • 7.5.6.1. Key country dynamics
      • 7.5.6.2. Regulatory framework/ reimbursement structure
      • 7.5.6.3. Competitive scenario
      • 7.5.6.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.6. Latin America
    • 7.6.1. Brazil
      • 7.6.1.1. Key country dynamics
      • 7.6.1.2. Regulatory framework/ reimbursement structure
      • 7.6.1.3. Competitive scenario
      • 7.6.1.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.6.2. Argentina
      • 7.6.2.1. Key country dynamics
      • 7.6.2.2. Regulatory framework/ reimbursement structure
      • 7.6.2.3. Competitive scenario
      • 7.6.2.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
  • 7.7. MEA
    • 7.7.1. South Africa
      • 7.7.1.1. Key country dynamics
      • 7.7.1.2. Regulatory framework/ reimbursement structure
      • 7.7.1.3. Competitive scenario
      • 7.7.1.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.2. Saudi Arabia
      • 7.7.2.1. Key country dynamics
      • 7.7.2.2. Regulatory framework/ reimbursement structure
      • 7.7.2.3. Competitive scenario
      • 7.7.2.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.3. UAE
      • 7.7.3.1. Key country dynamics
      • 7.7.3.2. Regulatory framework/ reimbursement structure
      • 7.7.3.3. Competitive scenario
      • 7.7.3.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.7.4. Kuwait
      • 7.7.4.1. Key country dynamics
      • 7.7.4.2. Regulatory framework/ reimbursement structure
      • 7.7.4.3. Competitive scenario
      • 7.7.4.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Recent Developments & Impact Analysis, By Key Market Participants
  • 8.2. Company/Competition Categorization
  • 8.3. Vendor Landscape
    • 8.3.1. List of key distributors and channel partners
    • 8.3.2. Key customers
    • 8.3.3. Key company market share analysis, 2024
    • 8.3.4. Pfizer Inc.
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. Merck & Co. Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. AbbVie Inc.
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Teva Pharmaceutical Industries Ltd
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Cipla
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Sun Pharmaceutical Industries Ltd.
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Lupin
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. Aurobindo Pharma Limited
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. Fresenius Kabi
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Viatris Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives

List of Tables

  • Table 1 List of abbreviation
  • Table 2 North America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 3 North America Aminoglycosides Market, by Route of, 2018 - 2030 (USD Million)
  • Table 4 North America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 5 U.S. Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 6 U.S. Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 7 U.S. Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 8 Canada Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 9 Canada Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 10 Canada Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 11 Mexico Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 12 Mexico Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 13 Mexico Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 14 Europe Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 15 Europe Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 16 Europe Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 17 Germany Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 18 Germany Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 19 Germany Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 20 UK Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 21 UK Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 22 UK Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 23 France Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 24 France Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 25 France Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 26 Italy Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 27 Italy Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 28 Italy Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 29 Spain Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 30 Spain Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 31 Spain Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 32 Asia Pacific Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 33 Asia Pacific Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 34 Asia Pacific Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 35 China Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 36 China Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 37 China Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 38 Japan Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 39 Japan Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 40 Japan Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 41 India Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 42 India Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 43 India Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 44 South Korea Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 45 South Korea Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 46 South Korea Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 47 Latin America Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 48 Latin America Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 49 Latin America Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 50 Brazil Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 51 Brazil Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 52 Brazil Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 53 MEA Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 54 MEA Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 55 MEA Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 56 South Africa Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 57 South Africa Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 58 South Africa Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 59 Saudi Arabia Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 60 Saudi Arabia Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 61 Saudi Arabia Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 62 UAE Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 63 UAE Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 64 UAE Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)
  • Table 65 Kuwait Aminoglycosides Market, by Product, 2018 - 2030 (USD Million)
  • Table 66 Kuwait Aminoglycosides Market, by Route of Administration, 2018 - 2030 (USD Million)
  • Table 67 Kuwait Aminoglycosides Market, by Application, 2018 - 2030 (USD Million)

List of Figures

  • Fig. 1 Aminoglycosides market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Value chain-based sizing & forecasting
  • Fig. 6 QFD modelling for market share assessment
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Product and route of administration segment snapshot
  • Fig. 10 Application segment snapshot
  • Fig. 11 Competitive landscape snapshot
  • Fig. 12 Pharmaceutical market, (USD Billion)
  • Fig. 13 Market dynamics
  • Fig. 14 Porter's five forces analysis
  • Fig. 15 PESTLE analysis
  • Fig. 16 Aminoglycosides market: Drug outlook and key takeaways
  • Fig. 17 Aminoglycosides market: Drug movement analysis
  • Fig. 18 Ergot alkaloids market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 19 Non-ergot Aminoglycosides market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 20 Aminoglycosides market: Product outlook and key takeaways
  • Fig. 21 Aminoglycosides market: Product movement analysis
  • Fig. 22 Neomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 23 Tobramycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 24 Gentamicin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 25 Amikacin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 26 Paromomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 27 Streptomycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 28 Kanamycin market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 29 Others market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 30 Aminoglycosides market: Route of administration outlook and key takeaways
  • Fig. 31 Aminoglycosides market: Route of administration movement analysis
  • Fig. 32 Injectablesmarket estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 33 Feed market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 34 Intra-mammary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 35 Topical market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 36 Oral market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 37 Aminoglycosides market: Application outlook and key takeaways
  • Fig. 38 Aminoglycosides market: Application channel movement analysis
  • Fig. 39 Skin Infection market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 40 UTI & Pelvic Diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 41 Veterinary market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 42 Respiratory diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 43 Other diseases market estimates and forecast, 2018 - 2030 (USD Million)
  • Fig. 44 Aminoglycosides market revenue, by region, 2024 & 2030 (USD Million)
  • Fig. 45 Regional marketplace: Key takeaways
  • Fig. 46 Regional marketplace: Key takeaways
  • Fig. 47 North America Aminoglycosides market estimates and forecasts, 2018 - 2030 ((USD Million))
  • Fig. 48 Key country dynamics
  • Fig. 49 Target disease prevalence
  • Fig. 50 U.S. Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 51 Key country dynamics
  • Fig. 52 Target disease prevalence
  • Fig. 53 Canada Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 54 Mexico Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 55 Key country dynamics
  • Fig. 56 Target disease prevalence
  • Fig. 57 Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 58 Key country dynamics
  • Fig. 59 Target disease prevalence
  • Fig. 60 UK Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 61 Key country dynamics
  • Fig. 62 Target disease prevalence
  • Fig. 63 Germany Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 64 Key country dynamics
  • Fig. 65 Target disease prevalence
  • Fig. 66 France Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 67 Key country dynamics
  • Fig. 68 Target disease prevalence
  • Fig. 69 Spain Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 70 Key country dynamics
  • Fig. 71 Target disease prevalence
  • Fig. 72 Italy Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 73 Key country dynamics
  • Fig. 74 Target disease prevalence
  • Fig. 75 Denmark Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 76 Key country dynamics
  • Fig. 77 Target disease prevalence
  • Fig. 78 Sweden Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 79 Key country dynamics
  • Fig. 80 Target disease prevalence
  • Fig. 81 Norway Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 82 Rest of Europe Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 83 Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 84 Key country dynamics
  • Fig. 85 Target disease prevalence
  • Fig. 86 Japan Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 87 Key country dynamics
  • Fig. 88 Target disease prevalence
  • Fig. 89 China Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 90 Key country dynamics
  • Fig. 91 Target disease prevalence
  • Fig. 92 India Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 93 Key country dynamics
  • Fig. 94 Target disease prevalence
  • Fig. 95 Australia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 96 Key country dynamics
  • Fig. 97 Thailand Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 98 Key country dynamics
  • Fig. 99 South Korea Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 100 Rest of Asia Pacific Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 101 Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 102 Key country dynamics
  • Fig. 103 Target disease prevalence
  • Fig. 104 Brazil Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 105 Key country dynamics
  • Fig. 106 Target disease prevalence
  • Fig. 107 Argentina Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 108 Rest of Latin America Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 109 MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 110 Key country dynamics
  • Fig. 111 Target disease prevalence
  • Fig. 112 South Africa Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 113 Key country dynamics
  • Fig. 114 Target disease prevalence
  • Fig. 115 Saudi Arabia Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 116 Key country dynamics
  • Fig. 117 Target disease prevalence
  • Fig. 118 UAE Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 119 Key country dynamics
  • Fig. 120 Target disease prevalence
  • Fig. 121 Kuwait Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)
  • Fig. 122 Rest of MEA Aminoglycosides market estimates and forecasts, 2018 - 2030 (USD Million)